Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled trial of MGCND00EP1 add-on therapy in pediatric treatment-resistant epilepsy
MOH_2021-03-22_009859Phase 2Not yet recruiting
- Sponsor
- Argent BioPharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CannEpil, cannabidiol and dronabinol in epilepsy (2 arms), sponsored by Argent BioPharma. Primary endpoints: Safety of MGCND00EP1 over 12 weeks and Efficacy of MGCND00EP1 over 12 weeks. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
CannEpilcannabidioldronabinol
03
Conditions
epilepsy
Beyond the preview
Go deeper on MOH_2021-03-22_009859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-03-22_009859.